Gilead Sciences, Inc. (FRA:GIS)
Germany
· Delayed Price · Currency is EUR | Market Cap | 107.00B |
| Revenue (ttm) | 26.59B |
| Net Income (ttm) | 5.52B |
| Shares Out | n/a |
| EPS (ttm) | 4.38 |
| PE Ratio | 19.39 |
| Forward PE | 11.77 |
| Dividend | 2.87 (3.33%) |
| Ex-Dividend Date | Jun 13, 2025 |
| Volume | 4,529 |
| Average Volume | 593 |
| Open | 86.51 |
| Previous Close | 87.54 |
| Day's Range | 84.61 - 86.51 |
| 52-Week Range | 57.29 - 111.84 |
| Beta | n/a |
| RSI | 29.00 |
| Earnings Date | Aug 1, 2025 |
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]
Financial Performance
In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.
Financial numbers in USD Financial StatementsNews
Fighting the World's Most Devastating Diseases Is the Focus of This Installment of "The Centrifuge Sessions"
NORTHAMPTON, MA / ACCESS Newswire / May 6, 2025 / At Gilead, we set and achieve bold ambitions in our fight against the world's most devastating diseases. In this installment of The Centrifuge Session...
Gilead: Sure, Why Not, But Not The CDRs
Notable healthcare headlines for the week: Gilead, CVS Health, Sanofi in focus
Stay updated on top pharmaceutical news: Merck's $3.9B SpringWorks deal, Hims & Hers' Wegovy partnership, CVS exiting Obamacare, and FDA updates on key drugs.
Gilead (GILD) Sees 24% Stock Surge Amid Tariff Resilience
Gilead (GILD) Sees 24% Stock Surge Amid Tariff Resilience
Gilead and Vertex Pharma named among biotech’s tariff safe havens
Gilead Sciences to Present at Upcoming Investor Conferences
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA Securities Health Care Conference on Tuesday, May 13 at 11:20 AM P...
Gilead Sciences to Present at Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA Securities Health Ca...
Gilead in $202M settlement with DoJ over kickbacks to doctors
Gilead Sciences agrees to pay $202 million to settle claims of kickbacks to doctors for HIV drug prescriptions
Gilead Sciences agreed to pay $202 million to the U.S. government and various states to settle claims the drugmaker used speaker programs to pay kickbacks to doctors to induce them to prescribe Gilead...
Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors
Gilead Sciences has reached a $202 million settlement to resolve a civil fraud lawsuit accusing the company of paying kickbacks to doctors who agreed to prescribe its HIV drugs, the U.S. attorney's of...
Gilead Sciences: AIDSVu Online Mapping Tool Helps Visualize HIV’s Impact in the United States
NORTHAMPTON, MA / ACCESS Newswire / April 29, 2025 / Gilead is committed to using its virology expertise to advance HIV treatment and prevention to help end the epidemic. Since 2010, the company has p...
Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis
– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in pe...
Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the Liver (EASL) Congress, May 7-10,...
SA analyst downgrades: TSLA, AAPL, T, PG, HPE, GILD, LRCX, ARCC
Gilead Sciences: Dividend Investors Must Be Cautious
Gilead Sciences offers steady dividend growth with a 2.99% yield. Read why the analyst nonetheless has a neutral rating on the stock.
Gilead Sciences (GILD) Adjusts EPS Outlook Despite Revenue Stability
Gilead Sciences (GILD) Adjusts EPS Outlook Despite Revenue Stability
Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks
As tariffs loom over the sector, biotechs with U.S.-based manufacturing and intellectual property are soothing investor concerns.
We're in a pharma stock pickers market, says Kessef's Len Yaffe
Len Yaffe, Kessef Capital Management, joins 'Fast Money' to talk opportunities in the pharma stock space.
Why Gilead Sciences Stock Slipped Today
How Is The Market Feeling About Gilead Sciences?
Gilead Sciences's (NYSE: GILD) short percent of float has fallen 4.44% since its last report. The company recently reported that it has 21.39 million shares sold short , which is 1.72% of all regular...
Gilead Sciences Q1 Earnings Review: HIV Division Masks Underperformance
Gilead Sciences Stock Falls as Slumping COVID-19, Cancer Drug Sales Hit Revenue
Gilead Sciences missed first-quarter revenue estimates as sales of its COVID-19 and cancer drugs declined.
AAPL Doubling India iPhone Production, TMUS Sells, GILD Healthcare Headwinds
Apple (AAPL) is expected to double its iPhone output from India to 80 million. Diane King Hall says the company is bracing to maneuver its production around tariffs aimed at China.